Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Aurella Alexandru"'
Autor:
Phuong Tran, Aurella Alexandru, S. Marimuthu, Tudor-Eliade Ciuleanu, Hiroshi Sakai, Manuel Cobo, Luis Paz-Ares, Michael Schenker, Jaafar Bennouna, Arnaud Scherpereel, Arteid Memaj, Enriqueta Felip, O. Juan-Vidal, David P. Carbone, B. Zurawski, Thomas John, Eduardo Richardet, Juliana Janoski de Menezes, Shun Lu, Martin Reck
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.9000-9000. ⟨10.1200/JCO.2021.39.15_suppl.9000⟩
Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.9000-9000. ⟨10.1200/JCO.2021.39.15_suppl.9000⟩
9000 Background: In the randomized phase 3 CheckMate 9LA trial (NCT03215706), first-line NIVO + IPI combined with 2 cycles of chemo significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) vs ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b2800a2aa277d299a7b3e6fbe4f791
https://www.hal.inserm.fr/inserm-03540833
https://www.hal.inserm.fr/inserm-03540833
Autor:
Michael Schenker, J. Yan, Manuel Cobo Dols, David P. Carbone, Arnaud Scherpereel, O. Juan-Vidal, Jaafar Bennouna, Luis Paz-Ares, S. Meadows-Shropshire, Tudor-Eliade Ciuleanu, Enriqueta Felip, Thomas John, B. Zurawski, Juliana Janoski de Menezes, Shun Lu, Aurella Alexandru, Eduardo Richardet, Hiroshi Sakai, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 38:9501-9501
9501 Background: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC in CheckMate 227 Part 1, regardless of PD-L1 expression. We hypothesized that a limited course of chemo combined with NIVO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8cb590313b3de1a63ac322c22bda955
https://doi.org/10.1200/jco.2020.38.15_suppl.9501
https://doi.org/10.1200/jco.2020.38.15_suppl.9501
